My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Natera, Inc. - Common Stock (NQ:NTRA)

209.50 +2.78 (+1.34%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 12, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Natera, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

7 Stocks to Buy in November in Light of Their October Dip ↗

November 15, 2021

October was a good month in the markets. It won't be easy to find stocks to buy on the dip. However, here are seven that will do the trick.

Via InvestorPlace

Medicare Coverage For Natera's Signatera For Pan-Cancer Immunotherapy Monitoring ↗

November 11, 2021

CMS Molecular Diagnostics Services Program (MolDX) has issued a final local coverage determination (LCD) for pan-cancer immunotherapy monitoring using Natera Inc...

Via Benzinga

Natera Raises FY21 Sales Outlook After Mixed Q3 earnings ↗

November 05, 2021

Natera Inc (NASDAQ: NTRA) posted Q3 sales of $158.1 million, +61% Y/Y, beating the consensus of $151.36 million, driven by an increase in test volume and product...

Via Benzinga

Natera Inc (NTRA) Q3 2021 Earnings Call Transcript ↗

November 05, 2021

NTRA earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

CEO And President Of Natera Trades $2.4M In Company Stock ↗

October 06, 2021

Leonard Steven Chapman, CEO And President at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on October 5, according to a new SEC filing. What Happened: A Form 4...

Via Benzinga

Topics Regulatory Compliance

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO ↗

August 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (...

Via Benzinga

Analyzing Natera's Unusual Options Activity ↗

August 04, 2021

On Wednesday, shares of Natera (NASDAQ:NTRA) saw unusual o...

Via Benzinga

What Does Natera's Debt Look Like? ↗

August 03, 2021

Over the past three months, shares of Natera (NASDAQ:NTRA) moved higher by 10.31%. Before we understand the importance of debt, let us look at how much debt Natera has....

Via Benzinga

The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗

November 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...

Via Benzinga

Notable Natera Insider Trades $3M In Company Stock ↗

September 30, 2021

Burkes Michael Brophy, Chief Financial Officer at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on September 28, according to a new SEC filing. What Happened:...

Via Benzinga

Topics Regulatory Compliance

Expert Ratings For Natera ↗

July 20, 2021

Within the last quarter, Natera (NASDAQ:NTRA) has observe...

Via Benzinga

Analyst Ratings For Natera ↗

June 22, 2021

Within the last quarter, Natera (NASDAQ:NTRA) has observed...

Via Benzinga

Expert Ratings for Natera ↗

May 25, 2021

Analysts have provided the following ratings for Natera (NASDAQ:NTRA) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 1 0 0...

Via Benzinga

Natera: Q1 Earnings Insights ↗

May 06, 2021

Shares of Natera (NASDAQ:NTRA) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 64.44% over the past year to ($0.74),...

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

CEO And President Of Natera Trades $3.41 Million In Company Stock ↗

September 27, 2021

Leonard Steven Chapman, CEO And President at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on September 24, according to a new SEC filing. What Happened: A...

Via Benzinga

Topics Regulatory Compliance

Return on Capital Employed Overview: Natera ↗

August 30, 2021

After pulling data from Benzinga Pro it seems like during Q2, Natera (NASDAQ:NTRA) brought in sales totaling $142.03 million. However, earnings decreased 82.96%, resulting in a...

Via Benzinga

Natera Q2 Sales Tops Street Estimates On Higher Volumes, Raises FY21 Sales Outlook ↗

August 06, 2021

Natera Inc's (NASDAQ: NTRA) second-quarter revenues jumped 64% Y/Y $142 million, driven by an increase in test volume and product revenues, sharply ahead of the consensus...

Via Benzinga

3 Stocks Insiders Are Buying ↗

July 27, 2021

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go...

Via Benzinga

Natera Sees Deeper Operating Losses In Q2 On Higher Commercialization Costs For New Product Offerings ↗

July 19, 2021

Natera Inc (NASDAQ: NTRA) expects 2Q'21 revenues of approximately $138 million to $141 million, equivalent to around 60% Y/Y growth. The Company's revenue...

Via Benzinga

This Explosive Biotech Is Taking On a Huge New Market ↗

June 30, 2021

Dominant in its core reproductive health market, niche medical diagnostics company Natera now has its sights on the crowded oncology diagnostics space.

Via The Motley Fool

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs ↗

August 01, 2021

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....

Via Benzinga

The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay ↗

July 21, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20) Alnylam Pharmaceuticals,...

Via Benzinga

10 Biggest Price Target Changes For Monday ↗

June 21, 2021

SVB Leerink raised Natera, Inc. (NASDAQ:NTRA) pr...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021 ↗

June 15, 2021

Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to Strong Buy. For the first quarter, Welltower had an...

Via Benzinga

Exact Sciences' First-Quarter Results Show Its Strength Under Pressure ↗

May 15, 2021

Despite ongoing pandemic-related headwinds, the medical diagnostic test maker's revenue grew. So how will it perform as those headwinds dissipate?

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021 ↗

May 25, 2021

Upgrades For Appian Corp (NASDAQ:APPN), Macquarie upgraded the previous rating of Underperform to Neutral. For the first quarter, Appian had an EPS of $0.06, compared to...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 06, 2021

Gainers T2 Biosystems (NASDAQ:TTOO) share...

Via Benzinga

The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs ↗

May 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:...

Via Benzinga

The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom ↗

May 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.